How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,008 results for

Spondyloarthropathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Serum apoprotein A1 levels are inversely associated with disease activity in gout: From a southern Chinese Han population. (PubMed)

(AS)/spondyloarthropathy (SpA), and 25 patients with osteoarthritis (OA). The serum levels of apoprotein A1 (Apo-A1) were significantly decreased in patients with gout when compared with RA, AS/SpA, and OA patients. The serum levels of CRP were significantly increased in gouty patients when compared with RA, AS/SpA, and OA patients. Furthermore, the serum levels of ESR were significantly increased in patients with gout compared to patients with OA. Correlation analysis indicated that the levels of Apo-A1 were

Full Text available with Trip Pro

2017 Medicine

182. Ankylosing Spondylitis Increases Perioperative and Postoperative Complications After Total Hip Arthroplasty. (PubMed)

Ankylosing Spondylitis Increases Perioperative and Postoperative Complications After Total Hip Arthroplasty. Ankylosing spondylitis (AS) is a chronic autoimmune spondyloarthropathy that primarily affects the axial spine and hips. Progressive disease leads to pronounced spinal kyphosis, positive sagittal balance, and altered biomechanics. The purpose of this study is to determine the complication profile of patients with AS undergoing total hip arthroplasty (THA).The Medicare sample was searched

2017 Journal of Arthroplasty

183. Familial Mediterranean fever patients with hidradenitis suppurativa. (PubMed)

characteristics of two unrelated patients with HS and familial Mediterranean fever (FMF).Case study.Besides FMF and HS, the first patient had acne conglobata, and the second patient had pyoderma gangrenosum and ankylosing spondyloarthropathy. Both patients had M694V/V726A MEFV gene mutations.PASH and PAPASH have recently been associated with genetic alterations of gene encoding proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1), which interacts with the product of MEFV gene

2017 International Journal of Dermatology

184. New developments in uveitis associated with HLA B27. (PubMed)

and some of the clinical implications of AAU. Progress has been made in the treatment of uveitis in general and in the treatment of uveitis in association with spondyloarthropathy in particular. The pathogenesis of AAU might derive clues from the above as well as from an understanding of the microbiome and possibly from knowledge derived from uveitis in association with Ebola.Although HLA B27-associated uveitis has been recognized since 1973, a variety of recent observations shed new light

2017 Current Opinion in Rheumatology

185. Low-trauma fractures without osteoporosis. (PubMed)

-trauma fractures do not have osteoporosis with DXA (i.e., T-score <-2.5), and some of them have no decreased BMD at all. Some medical conditions (spondyloarthropathies, chronic kidney disease and mineral bone disorder, diabetes, obesity) or drugs (glucocorticoids, aromatase inhibitors) are more prone to cause fractures with subnormal BMD. In the situation of fragility fractures with subnormal or normal BMD, clinicians face a difficulty as almost all the pharmacologic treatments have proved

2017 Osteoporosis International

186. The unresolved problem of beta-2 microglobulin amyloid deposits in the intervertebral discs of long-term dialysis patients (PubMed)

The unresolved problem of beta-2 microglobulin amyloid deposits in the intervertebral discs of long-term dialysis patients Dialysis-related destructive spondyloarthropathy caused by beta-2 microglobulin (β2M) amyloid deposits in intervertebral discs is a major burden for patients undergoing long-term dialysis. This study aimed to quantify the presence of β2M amyloid deposits in the intervertebral disc tissue of such patients and analyze whether there was a significant correlation between β2M

Full Text available with Trip Pro

2017 Journal of orthopaedic surgery and research

187. Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies—New Therapeutic Possibilities? (PubMed)

Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies—New Therapeutic Possibilities? Considerable progress has been made recently in understanding the complex pathogenesis and treatment of spondyloarthropathies (SpA). Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Although they adequately control

Full Text available with Trip Pro

2017 International journal of molecular sciences

188. Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038)

with spondyloarthropathy and 1 or more of the following spondyloarthritis (SpA) characteristics: • Inflammatory back pain • Arthritis (physician-diagnosed) • Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia) • Dactylitis (physician-diagnosed) • Psoriasis (physician-diagnosed) • History of physician-diagnosed inflammatory bowel disease (IBD) • History of uveitis confirmed by an ophthalmologist • Good response

2017 Clinical Trials

189. Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain

as a blood donor Objection by General Practitioner to trial entry Poor venous access Also for osteoarthritis patients: History of inflammatory arthritis, including rheumatoid arthritis, seronegative spondyloarthropathy (eg ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease related arthropathy), gout, pseudogout in index knee (as diagnosed by appropriate crystals on aspiration or C-reactive protein elevation during attacks (subjects with gout or pseudogout in a joint other than

2017 Clinical Trials

190. Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

or other undifferentiated spondyloarthropathy, or Type III Modic changes around the target disc. Clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology. Clinical suspicion of facet pain as primary pain generator. Subjects who test positive for communicable disease, have significant systemic disease, or are prone to infection. Patient who are deemed unsuitable for clinical study participation by the investigator. Contacts and Locations Go to Information

2017 Clinical Trials

191. A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

, in the opinion of the investigator Pregnant or lactating female subjects, or subjects who are planning to conceive or breastfeed during the study period or within 12 months after the last administration. History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, pulmonary fibrosis, or Felty's syndrome

2017 Clinical Trials

192. The Effects of Intradialytic Exercise in Hemodiafiltration Patients

to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Dialysis vintage more than 3 months Sedentary or light physical activity Exclusion Criteria: recent myocardial infarction (<12 months) recent ischemic stroke (<12months) uncontrolled comorbidities (diabetes/hypertension/heart failure/heart disease/respiratory disease) Life expectancy < 12 months active musculoskeletal problem e.g.) rheumatoid arthritis, spondyloarthropathy

2017 Clinical Trials

193. Description of Spondylarthritis and Validation of ASAS Criteria in West Indian Patients Seen in Consultation of Rheumatology.

of spondyloarthropathies to allow for early diagnosis, Nuclear magnetic resonance imaging (MRI). This approach led to the publication in 2009 of the classification criteria for spondylarthritis, in particular axial spondyloarthritis, as well as a proposal to modify the classification of criteria defined by Mr. Amor (AMOR) and European Spondylarthropathy Study Group (ESSG) criteria, taking into account the potential abnormalities visible in Magnetic Resonance Imaging Nuclear (MRI). The performance (specificity

2017 Clinical Trials

194. Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants

body fracture, piriformis syndrome, femoral acetabular impingement, labral tear or hip osteoarthritis. Patients with low back pain VAS ratings more than 50 should be carefully considered; they should not participate if the investigator believes these non-SIJ conditions would impair improvement from SIJ treatment. SI joint dysfunction due to an alternative explanation such as: Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy) Tumor Infection Acute

2017 Clinical Trials

195. Evaluation of Platelet Rich Plasma (PRP) for Knee Osteoarthritis

medication in any other joint less than 1 month after inclusion; Introduction of any medical or physiotherapeutic intervention in the last 3 months (rehabilitation, acupuncture, cane, orthotics, etc.) for locomotor system; Body Mass Index (BMI) greater than 35. Presence of other types of arthropathies such as rheumatoid arthritis, diffuse connective tissue diseases, microcrystalline arthropathies, spondyloarthropathies and infectious arthropathies. Symptomatic osteoarthritis of hip and feet Presence

2017 Clinical Trials

196. A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions

or prior history of malignancy. Overt or active bacterial infection, either local or systemic. Has undergone systemic administration of any type of corticosteroid, anti-neoplastic, immunostimulating, or immunosuppressive agents within 30 days prior to implantation of the assigned treatment. Comorbidities precluding subject from being a surgical candidate. History of autoimmune disease known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis

2017 Clinical Trials

197. 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

Study Details Study Description Go to Brief Summary: Twenty evaluable patients with clinical suspicion or confirmed diagnosis of spondyloarthritis due to ankylosing spondylitis, or associated with other known clinical conditions like inflammatory bowel disease, psoriatic arthritis, or undifferentiated spondyloarthropathy. Five patients will be recruited in the first part of the trial, as a Proof of Concept (PoC) phase. The PoC phase will assess the imaging potential of 99mTc-rhAnnexin V-128 in terms

2017 Clinical Trials

198. Benepali® PEN Patient Satisfaction Survey

of the training material received. Condition or disease Intervention/treatment Rheumatoid Arthritis Spondyloarthropathies Biological: Benepali Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 500 participants Observational Model: Case-Only Time Perspective: Cross-Sectional Official Title: Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen Actual Study Start Date : August 10, 2017 Actual Primary Completion Date

2017 Clinical Trials

199. Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®

be stable within the last 4 weeks prior to screening Exclusion Criteria: The patient will be deemed ineligible for the study meeting any of the following criteria: Other inflammatory arthropathies apart from rheumatoid arthritis (e.g. gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme desease) or other system autoimmune diseases (e.g. systemic lupus erythematosus, inflammatory bowel disease, pneumosclerosis or Felly's syndrome, sclerodermia, inflammatory myopathy

2017 Clinical Trials

200. Chronic Inflammatory Disease, Lifestyle and Treatment Response

(score) Rheumatoid Arthritis: Disease-specific core outcome sets-7 [ Time Frame: week 14-16 ] • C-Reactive protein (mg/l) Rheumatoid Arthritis: Disease-specific core outcome sets-8 [ Time Frame: week 14-16 ] • DAS28-CRP (score) Rheumatoid Arthritis: Disease-specific core outcome sets-9 [ Time Frame: week 14-16 ] • Simplified Disease Activity Index (SDAI) (index) Axial Spondyloarthropathy: Disease-specific core outcome sets-1 [ Time Frame: week 14-16 ] • BASFI (score) Axial Spondyloarthropathy (...) : Disease-specific core outcome sets-2 [ Time Frame: week 14-16 ] • BASDAI (score) Axial Spondyloarthropathy: Disease-specific core outcome sets-3 [ Time Frame: week 14-16 ] • BASMI (score) Axial Spondyloarthropathy: Disease-specific core outcome sets-4 [ Time Frame: week 14-16 ] • Total score for back pain (0-100 mm VAS) Axial Spondyloarthropathy: Disease-specific core outcome sets-5 [ Time Frame: week 14-16 ] • Physician global assessment (0-100 mm VAS) Axial Spondyloarthropathy: Disease-specific core

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>